Lsl Pharma Group Inc (LSL.VN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 09-2020 | |
| Sales | 17,748 | 10,028 | 8,214 | 8,771 | 4,823 |
| Cost of Goods | 12,400 | 8,383 | 10,386 | 6,246 | 4,315 |
| Gross Profit | 5,348 | 1,645 | -2,172 | 2,525 | 508 |
| Operating Expenses | 4,942 | 5,599 | 4,585 | 2,591 | -302 |
| Operating Income | 406 | -3,954 | -6,757 | -65 | 809 |
| Interest Expense | 1,746 | 1,570 | 1,268 | 1,587 | 535 |
| Other Income | 4,707 | -2,948 | -37 | 23 | -192 |
| Pre-tax Income | 3,367 | -8,472 | -8,062 | -1,629 | 83 |
| Income Tax | 50 | N/A | N/A | 147 | -5 |
| Net Income Continuous | 3,317 | -8,472 | -8,062 | -1,777 | 88 |
| Net Income | $3,317 | $-8,472 | $-8,062 | $-1,777 | $88 |
| EPS Basic Total Ops | 0.03 | -0.11 | -0.10 | -0.01 | 0.00 |
| EPS Basic Continuous Ops | 0.03 | -0.11 | N/A | -0.01 | 0.00 |
| EPS Diluted Total Ops | 0.03 | -0.11 | -0.10 | -0.01 | 0.00 |
| EPS Diluted Continuous Ops | 0.03 | -0.11 | N/A | -0.01 | 0.00 |
| EBITDA(a) | $6,622 | $-5,773 | $-5,747 | $932 | $991 |